Comparative Pharmacology
Head-to-head clinical analysis: ADDERALL 10 versus FOCALIN XR.
Head-to-head clinical analysis: ADDERALL 10 versus FOCALIN XR.
ADDERALL 10 vs FOCALIN XR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Adderall 10 contains a mixture of amphetamine salts (dextroamphetamine and levoamphetamine). Amphetamines are non-catecholamine sympathomimetic amines that promote the release of dopamine and norepinephrine from presynaptic neurons, inhibit their reuptake, and inhibit monoamine oxidase activity, thereby increasing extracellular levels of these neurotransmitters in the central nervous system.
Focalin XR (dexmethylphenidate) is a central nervous system stimulant. It blocks the reuptake of norepinephrine and dopamine into presynaptic neurons, increasing their concentrations in the synaptic cleft. The d-threo enantiomer is pharmacologically active.
10 mg orally once daily in the morning, with or without food; may increase by 5-10 mg weekly based on tolerability and response; usual effective dose 10-40 mg/day divided into 2-3 doses; maximum 60 mg/day.
Initial 20 mg orally once daily; may increase in 10-20 mg increments at weekly intervals; maximum 60 mg/day.
None Documented
None Documented
Terminal elimination half-life: dextroamphetamine 9-11 hours, levoamphetamine 11-14 hours (Adderall is a mixed salt). In adults, mean half-life ~10 hours; in children, slightly shorter (6-8 hours). Clinical context: steady-state reached in 2-3 days; dosing interval typically 4-6 hours for immediate-release.
Terminal half-life: 2-3 hours for immediate-release; 6-8 hours for extended-release (FOCALIN XR)
Renal: 70-80% (30-40% as unchanged amphetamine; remainder as deaminated and hydroxylated metabolites). Fecal: minimal (<5%). Biliary: negligible. Urinary pH affects excretion: acidic urine increases elimination, alkaline urine decreases.
Renal (approximately 90% as unchanged drug and metabolites)
Category C
Category C
CNS Stimulant
CNS Stimulant